SLC5A2 and kidney disorder: More recently, the addition of sodium-glucose cotransporter type 2 (SGLT2) inhibitors, in particular, canagliflozin in CREDENCE, dapagliflozin in DAPA-CKD, and empagliflozin in EMPA-KIDNEY, to renin-angiotensin system blockade has shown benefit in persons with CKD in terms of reducing kidney disease progression and the occurrence of CV events [16–18].